[引用][C] Clinical Development of Gefitinib in Non–Small-Cell Lung Cancer and the Iressa® Survival Evaluation in Lung Cancer Trial

N Price, CP Belani - Clinical Lung Cancer, 2005 - Elsevier
• Epidermal growth factor receptor (EGFR) is an important target for anticancer therapy.
Monoclonal antibodies against EGFRs and small molecule inhibitors have entered clinical …
被引用次数：1 相关文章 所有 5 个版本

Gefitinib in non-small cell lung cancer

K Tamura, M Fukuoka - Expert opinion on pharmacotherapy, 2005 - Taylor & Francis
Gefitinib (IressaTM), an orally-active tyrosine kinase inhibitor of the epidermal growth factor
receptor (EGFR), is the first approved molecular-targeted drug for the management of …
被引用次数：98 相关文章 所有 3 个版本

Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience

A Kommareddy, MA Coplin, F Gao, D Behnken… - Lung Cancer, 2004 - Elsevier
Gefitinib has modest activity with an overall response rate of 11–18% in patients with
metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following …
被引用次数：23 相关文章 所有 8 个版本

Gefitinib in patients with non-small cell lung cancer (NSCLC): the Royal Marsden experience

M Parton, N Maisey, S Banerjee… - Journal of Clinical …, 2004 - ascopubs.org
7099 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain,
has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). The clinical …
被引用次数：3 相关文章

Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer

M Nishikawa, N Kusano, N Yoshimoto, M Ito… - Gan to Kagaku ryoho …, 2006 - europepmc.org
The purpose of this study was to evaluate the survival outcome in patients with advanced
and previously treated non-small cell lung cancer given gefitinib (GEF) at our institution. We …
相关文章 所有 2 个版本

Gefitinib in the treatment of advanced non-small-cell lung cancer

M Reck - Expert Review of Anticancer Therapy, 2009 - Taylor & Francis
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor, even after platinum-based chemotherapy. EGF …
被引用次数：35 相关文章 所有 5 个版本

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients

A Pircher, F Ploner, H Popper, W Hilbe - Lung cancer, 2010 - Elsevier
In 2002 results of two-phase II studies with the new epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) gefitinib showed not only promising efficacy in second and …
被引用次数：13 相关文章 所有 9 个版本

Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania

ML Veronese, K Algazy, L Bearn, B Eaby… - Cancer …, 2005 - Taylor & Francis
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
被引用次数：22 相关文章 所有 2 个版本
[PDF] niph.go.jp

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer

M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
被引用次数：3958 相关文章 所有 15 个版本

Gefitinib (Iressa) trials in non-small cell lung cancer

DH Johnson - Lung Cancer, 2003 - Elsevier
Gefitinib (Iressa™) is a synthetic anilinoquinazoline capable of inhibiting the epidermal
growth factor receptor tyrosine kinase in vitro at nanomolar concentrations. In phase I trials …
被引用次数：53 相关文章 所有 8 个版本